{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:59:52Z","timestamp":1791993592467,"version":"4.4.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1124\/molpharm.121.000354","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T11:13:38Z","timestamp":1639480418000},"page":"168-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin"],"prefix":"10.1016","volume":"101","author":[{"given":"Fereshteh","family":"Ahmadinejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasia","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Britt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Koblinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Souers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Leverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gewirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.121.000354_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1667\/RR14202.1","article-title":"Radiosensitization by PARP inhibition in DNA repair proficient and deficient tumor cells: proliferative recovery in senescent cells","volume":"185","author":"Alotaibi","year":"2016","journal-title":"Radiat Res"},{"key":"10.1124\/molpharm.121.000354_bib2","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1124\/molpharm.121.000354_bib3","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"Argiris","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/molpharm.121.000354_bib4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10600","article-title":"Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders","volume":"479","author":"Baker","year":"2011","journal-title":"Nature"},{"key":"10.1124\/molpharm.121.000354_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2010\/201367","article-title":"Cellular responses to cisplatin-induced DNA damage","volume":"2010","author":"Basu","year":"2010","journal-title":"J Nucleic Acids"},{"key":"10.1124\/molpharm.121.000354_bib6","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1093\/emboj\/cdg417","article-title":"Reversal of human cellular senescence: roles of the p53 and p16 pathways","volume":"22","author":"Beaus\u00e9jour","year":"2003","journal-title":"EMBO J"},{"key":"10.1124\/molpharm.121.000354_bib7","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1158\/1078-0432.CCR-20-4084","article-title":"EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)","volume":"27","author":"Bertino","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1124\/molpharm.121.000354_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114765","article-title":"Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy","volume":"193","author":"Carpenter","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.121.000354_bib9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41419-019-2150-8","article-title":"Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck","volume":"10","author":"Carter","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1124\/molpharm.121.000354_bib10","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-11-0415","article-title":"The Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro in vivo","volume":"10","author":"Chen","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/molpharm.121.000354_bib11","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.4161\/cc.28402","article-title":"Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers","volume":"13","author":"Chitikova","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1124\/molpharm.121.000354_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and Neck Cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/molpharm.121.000354_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"10.1124\/molpharm.121.000354_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41571-019-0227-z","article-title":"The changing therapeutic landscape of head and neck cancer","volume":"16","author":"Cramer","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/molpharm.121.000354_bib15","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/nprot.2009.191","article-title":"Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo","volume":"4","author":"Debacq-Chainiaux","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1124\/molpharm.121.000354_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1124\/molpharm.121.000354_bib17","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1073\/pnas.92.20.9363","article-title":"A biomarker that identifies senescent human cells in culture and in aging skin in vivo","volume":"92","author":"Dimri","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.121.000354_bib18","doi-asserted-by":"crossref","first-page":"11731","DOI":"10.1074\/jbc.C300023200","article-title":"Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53","volume":"278","author":"Dirac","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.121.000354_bib19","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/microorganisms8101498","article-title":"Evolving profile of HPV-driven oropharyngeal squamous cell carcinoma in a national cancer institute in Italy: A 10-year retrospective study","volume":"8","author":"Don\u00e0","year":"2020","journal-title":"Microorganisms"},{"key":"10.1124\/molpharm.121.000354_bib20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/2159-8290.CD-20-1375","article-title":"Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence","volume":"11","author":"Duy","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1124\/molpharm.121.000354_bib21","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1158\/1078-0432.CCR-04-1462","article-title":"Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response","volume":"11","author":"Elmore","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/molpharm.121.000354_bib22","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/jnci\/djq364","article-title":"Therapy-induced senescence in cancer","volume":"102","author":"Ewald","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/molpharm.121.000354_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0378-4274(88)90024-0","article-title":"Cisplatin pharmacokinetics: applications of a physiological model","volume":"43","author":"Farris","year":"1988","journal-title":"Toxicol Lett"},{"key":"10.1124\/molpharm.121.000354_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2407-6-213","article-title":"Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line","volume":"6","author":"Fiebig","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1124\/molpharm.121.000354_bib25","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2005.01.057","article-title":"Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group","volume":"23","author":"Gibson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1124\/molpharm.121.000354_bib26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc2933","article-title":"Does tumour dormancy offer a therapeutic target?","volume":"10","author":"Goss","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/molpharm.121.000354_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13287-018-0857-6","article-title":"Effects of senolytic drugs on human mesenchymal stromal cells","volume":"9","author":"Grezella","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"10.1124\/molpharm.121.000354_bib28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood-2019-130158","article-title":"Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis","volume":"134(Suppl)","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"10.1124\/molpharm.121.000354_bib29","first-page":"2856","article-title":"Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity","volume":"9","author":"Hayward","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1124\/molpharm.121.000354_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1124\/molpharm.121.000354_bib31","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1016\/j.cub.2017.07.033","article-title":"Unmasking Transcriptional Heterogeneity in Senescent Cells","volume":"27","author":"Hernandez-Segura","year":"2017","journal-title":"Curr Biol"},{"key":"10.1124\/molpharm.121.000354_bib32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","article-title":"Hallmarks of Cellular Senescence","volume":"28","author":"Hernandez-Segura","year":"2018","journal-title":"Trends Cell Biol"},{"key":"10.1124\/molpharm.121.000354_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2008.07.011","article-title":"Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer","volume":"272","author":"Jeon","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1124\/molpharm.121.000354_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jtbi.2016.01.024","article-title":"Escape from tumor dormancy and time to angiogenic switch as mitigated by tumor-induced stimulation of stroma","volume":"395","author":"Kareva","year":"2016","journal-title":"J Theor Biol"},{"key":"10.1124\/molpharm.121.000354_bib35","article-title":"Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.121.000354_bib36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","article-title":"Senescence of activated stellate cells limits liver fibrosis","volume":"134","author":"Krizhanovsky","year":"2008","journal-title":"Cell"},{"key":"10.1124\/molpharm.121.000354_bib37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/cancers13030386","article-title":"Senolytic targeting of Bcl-2 anti-apoptotic family increases cell death in irradiated sarcoma cells","volume":"13","author":"Lafontaine","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1124\/molpharm.121.000354_bib38","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2018.36.15_suppl.2594","article-title":"A phase I study of novel dual Bcl-2\/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor","volume":"36(Suppl)","author":"Lakhani","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1124\/molpharm.121.000354_bib39","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.radonc.2009.08.038","article-title":"Incidence of isolated regional recurrence after definitive (chemo-) radiotherapy for head and neck squamous cell carcinoma","volume":"93","author":"Lambrecht","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1124\/molpharm.121.000354_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/molpharm.121.000354_bib41","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/ijms22041527","article-title":"Bcl-xL as a Modulator of Senescence and Aging","volume":"22","author":"Mas-Bargues","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/molpharm.121.000354_bib42","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1182\/blood-2011-12-400929","article-title":"Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells","volume":"119","author":"M\u00e9rino","year":"2012","journal-title":"Blood"},{"key":"10.1124\/molpharm.121.000354_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/951574","article-title":"Role of p16(INK4A) in replicative senescence and DNA damage-induced premature senescence in p53-deficient human cells","volume":"2012","author":"Mirzayans","year":"2012","journal-title":"Biochem Res Int"},{"key":"10.1124\/molpharm.121.000354_bib44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-08-1754","article-title":"Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence","volume":"15","author":"Morgan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1124\/molpharm.121.000354_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrc3057","article-title":"Pro-senescence therapy for cancer treatment","volume":"11","author":"Nardella","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/molpharm.121.000354_bib46","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1124\/molpharm.121.000354_bib47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated Bcl-2\/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Commun Biol"},{"key":"10.1124\/molpharm.121.000354_bib48","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<164::AID-CNCR23>3.0.CO;2-Q","article-title":"Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck","volume":"85","author":"Pena","year":"1999","journal-title":"Cancer"},{"key":"10.1124\/molpharm.121.000354_bib49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrc3773","article-title":"Inside and out: the activities of senescence in cancer","volume":"14","author":"P\u00e9rez-Mancera","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/molpharm.121.000354_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5416923","article-title":"Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int"},{"key":"10.1124\/molpharm.121.000354_bib51","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.2217\/fon-2021-0140","article-title":"A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors","volume":"17","author":"Puglisi","year":"2021","journal-title":"Future Oncol"},{"key":"10.1124\/molpharm.121.000354_bib52","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/jco.2011.29.15_suppl.2518","article-title":"A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors","volume":"29(Suppl)","author":"Puglisi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1124\/molpharm.121.000354_bib53","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cellbi.2008.04.021","article-title":"Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy","volume":"32","author":"Puig","year":"2008","journal-title":"Cell Biol Int"},{"key":"10.1124\/molpharm.121.000354_bib54","first-page":"4438","article-title":"Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo","volume":"55","author":"Raffo","year":"1995","journal-title":"Cancer Res"},{"key":"10.1124\/molpharm.121.000354_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.08.011","article-title":"Targeting senescence pathways to reverse drug resistance in cancer","volume":"219","author":"Rebbaa","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1124\/molpharm.121.000354_bib56","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biocel.2015.03.020","article-title":"Bcl-xL stimulates Bax relocation to mitochondria and primes cells to ABT-737","volume":"64","author":"Renault","year":"2015","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1124\/molpharm.121.000354_bib57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1667\/RR3185.1","article-title":"Cisplatin enhances the formation of DNA single- and double-strand breaks by hydrated electrons and hydroxyl radicals","volume":"179","author":"Rezaee","year":"2013","journal-title":"Radiat Res"},{"key":"10.1124\/molpharm.121.000354_bib58","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-04-1270","article-title":"Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers","volume":"65","author":"Roberson","year":"2005","journal-title":"Cancer Res"},{"key":"10.1124\/molpharm.121.000354_bib59","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/jco.2009.27.15_suppl.3505","article-title":"Ongoing phase I studies of ABT-263: Mitigating Bcl-X L induced thrombocytopenia with lead-in and continuous dosing","volume":"27(Suppl)","author":"Roberts","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/molpharm.121.000354_bib60","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1124\/molpharm.121.000354_bib61","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/cancers12040822","article-title":"Therapy-Induced Senescence: An \u201cOld\u201d Friend Becomes the Enemy","volume":"12","author":"Saleh","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1124\/molpharm.121.000354_bib62","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/1878-0261.12761","article-title":"Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL -BAX interaction","volume":"14","author":"Saleh","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1124\/molpharm.121.000354_bib63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bcp.2018.12.013","article-title":"Tumor cell escape from therapy-induced senescence","volume":"162","author":"Saleh","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.121.000354_bib64","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1128\/MCB.21.5.1552-1564.2001","article-title":"Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53","volume":"21","author":"Seluanov","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1124\/molpharm.121.000354_bib65","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.4161\/15548627.2014.993283","article-title":"A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089","volume":"10","author":"Sharma","year":"2014","journal-title":"Autophagy"},{"key":"10.1124\/molpharm.121.000354_bib66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc3960","article-title":"Forging a signature of in vivo senescence","volume":"15","author":"Sharpless","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/molpharm.121.000354_bib67","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/sj.onc.1207518","article-title":"Hallmarks of senescence in carcinogenesis and cancer therapy","volume":"23","author":"Shay","year":"2004","journal-title":"Oncogene"},{"key":"10.1124\/molpharm.121.000354_bib68","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V108.11.1107.1107","article-title":"The Bcl-2 family inhibitor ABT-263 shows significant but reversible thrombocytopenia in mice","volume":"108","author":"Shoemaker","year":"2006","journal-title":"Blood"},{"key":"10.1124\/molpharm.121.000354_bib69","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tcb.2018.04.006","article-title":"Two-step senescence-focused cancer therapies","volume":"28","author":"Sieben","year":"2018","journal-title":"Trends Cell Biol"},{"key":"10.1124\/molpharm.121.000354_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160901","article-title":"Genomic alteration in head and neck squamous cell carcinoma (HNSCC) cell lines inferred from karyotyping, molecular cytogenetics, and array comparative genomic hybridization","volume":"11","author":"Singchat","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.121.000354_bib71","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrc3793","article-title":"Mechanisms of disseminated cancer cell dormancy: an awakening field","volume":"14","author":"Sosa","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/molpharm.121.000354_bib72","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/cells9020346","article-title":"Beyond tumor suppression: Senescence in cancer stemness and tumor dormancy","volume":"9","author":"Triana-Mart\u00ednez","year":"2020","journal-title":"Cells"},{"key":"10.1124\/molpharm.121.000354_bib73","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1124\/molpharm.121.000354_bib74","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2125.2004.02082.x","article-title":"Population pharmacokinetics of total and unbound plasma cisplatin in adult patients","volume":"57","author":"Urien","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/molpharm.121.000354_bib75","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43653","article-title":"CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors","volume":"8","author":"Walens","year":"2019","journal-title":"eLife"},{"key":"10.1124\/molpharm.121.000354_bib76","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.18632\/oncotarget.12242","article-title":"Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/molpharm.121.000354_bib77","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ijc.27810","article-title":"Polyploidy road to therapy-induced cellular senescence and escape","volume":"132","author":"Wang","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1124\/molpharm.121.000354_bib78","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1096\/fj.04-2047com","article-title":"Bcl-XL disrupts death-inducing signal complex formation in plasma membrane induced by hypoxia\/reoxygenation","volume":"18","author":"Wang","year":"2004","journal-title":"FASEB J"},{"key":"10.1124\/molpharm.121.000354_bib79","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/acel.12632","article-title":"Analysis of individual cells identifies cell-to-cell variability following induction of cellular senescence","volume":"16","author":"Wiley","year":"2017","journal-title":"Aging Cell"},{"key":"10.1124\/molpharm.121.000354_bib80","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/diagnostics10030144","article-title":"Circulating tumor cells as a tool of minimal residual disease can predict lung cancer recurrence: A longitudinal, prospective trial","volume":"10","author":"Wu","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1124\/molpharm.121.000354_bib81","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11357-020-00154-8","article-title":"Pharmacological or genetic depletion of senescent astrocytes prevents whole brain irradiation-induced impairment of neurovascular coupling responses protecting cognitive function in mice","volume":"42","author":"Yabluchanskiy","year":"2020","journal-title":"Geroscience"},{"key":"10.1124\/molpharm.121.000354_bib82","doi-asserted-by":"crossref","first-page":"17049","DOI":"10.1038\/cddiscovery.2017.49","article-title":"Tumor cell senescence response produces aggressive variants","volume":"3","author":"Yang","year":"2017","journal-title":"Cell Death Discov"},{"key":"10.1124\/molpharm.121.000354_bib83","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1158\/0008-5472.CAN-15-1370","article-title":"Mechanisms of cancer cell dormancy\u2014another hallmark of cancer?","volume":"75","author":"Yeh","year":"2015","journal-title":"Cancer Res"},{"key":"10.1124\/molpharm.121.000354_bib84","doi-asserted-by":"crossref","first-page":"11190","DOI":"10.1038\/ncomms11190","article-title":"Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL","volume":"7","author":"Yosef","year":"2016","journal-title":"Nat Commun"},{"key":"10.1124\/molpharm.121.000354_bib85","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/acel.12445","article-title":"Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors","volume":"15","author":"Zhu","year":"2016","journal-title":"Aging Cell"},{"key":"10.1124\/molpharm.121.000354_bib86","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/acel.12344","article-title":"The Achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs","volume":"14","author":"Zhu","year":"2015","journal-title":"Aging Cell"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.121.000354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:48:43Z","timestamp":1739936923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24011970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0026895X24011970"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.121.000354","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.121.000354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}